Physician profile
Brett Sobieralski
NPI 1649405218
$3,625.78
in general payments reported to CMS, 2019-2025
18 companies · $651 in 2025
The $651 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $224 · 2021: $344 · 2022: $279 · 2023: $455 · 2024: $619 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $640.07 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $437.95 | 2019-2021 | |
| Abbvie INC. | $432.23 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Allergan, INC. | $417.51 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $283.85 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Shire North American Group INC | $244.11 | 2019 | |
| Sun Pharmaceutical Industries INC. | $239.65 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $177.99 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $169.92 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $133.30 | 2019-2021 | |
| Oyster Point Pharma, INC. | $120.70 | 2023-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $106.71 | 2023 | Acthar |
| Johnson & Johnson Vision Care, INC. | $61.26 | 2020-2024 | |
| Coopervision INC. | $49.08 | 2021 | |
| Dompe US, INC. | $46.69 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $24.20 | 2020 | |
| Thea Pharma INC. | $23.10 | 2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $17.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Sobieralski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.